Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET

Company Participants

Erick Lucera – Executive Vice President and Chief Financial Officer
Cristi Barnett – Senior Vice President, Corporate Communications and Investor Relations

Conference Call Participants

Liisa Bayko – Evercore ISI

Liisa Bayko

Okay, welcome everyone. This is Evercore’s Healthcare Conference. I’m Liisa Bayko, one of this mid-cap analysts here at Evercore, and I’ve been covering Editas as one of the gene editing companies that we’ve been working with over my time at Evercore, and it’s been really fun to watch your progress. So looking forward to getting into it with Erick, CFO, and we have IR here as well with Cristi. And so we’ll go ahead and get started. Why don’t we start with giving us a company overview.

Erick Lucera

Well thank you Liisa for having us. You guys have been a great partner with us over the years and with me personally for a long time. So thank you. Honored to be here.

So I’d say where Editas is the best way to think about what the company is to think along the lines of our three pillar strategy. The first meaning Renocel, the second being our in vivo program, and the third being our out-licensing of our IP, which we think of as its own little business. So with respect to Renocel, as you may have seen, we recently announced our intention to find a partner for that, and that is ongoing. But we think that it is a very, very good asset with respect to where some of the other sickle cell products are. We think we have the potential for a best-in-class medicine and we’re going to have an update in a little under a week at ASH next week in San Diego. So if you guys are there, Cristi will be